Novo Nordisk (NVO) said Tuesday it expects 2026 adjusted sales to decline by 5% to 13%.
Analysts surveyed by FactSet expect $47.07 billion.
"The outlook reflects expectations for sales growth within International Operations and expectations for a sales decline within US Operations," the company said.
Shares of Novo Nordisk were down more than 12% in recent Tuesday trading.
Price: 51.68, Change: -7.25, Percent Change: -12.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments